上海莱士(002252.SZ)公告称，公司于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了Ⅱb期临床试验登记信息，试验药物为SR604注射液，用于血友病A/B及先天性凝血因子Ⅶ缺乏症患者的出血预防治疗。该药物已完成Part A剂量递增Ⅰ期试验和Part B疗效探索Ⅱa期试验，目前正在进行Part C疗效探索Ⅱb期试验。该品种研制成功，有望显著改善血友病患者的用药体验。截至公告披露日，全球尚无与该药物同靶点的产品上市。
上海莱士(002252.SZ)公告称，公司于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了Ⅱb期临床试验登记信息，试验药物为SR604注射液，用于血友病A/B及先天性凝血因子Ⅶ缺乏症患者的出血预防治疗。该药物已完成Part A剂量递增Ⅰ期试验和Part B疗效探索Ⅱa期试验，目前正在进行Part C疗效探索Ⅱb期试验。该品种研制成功，有望显著改善血友病患者的用药体验。截至公告披露日，全球尚无与该药物同靶点的产品上市。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.